IC-MPGN: Clinical Trials

1 trial for IC-MPGN, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 21Terminated 1

Follow IC-MPGN: new trials by email Literature Review of IC-MPGN trials Research Report on IC-MPGN

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471
Danicopan - C3 Glomerulonephritis, C3 Glomerulopathy
Phase 2TerminatedAlexion Pharmaceuticals, Inc.222018-06-202023-08-21

Narrower conditions

Glomerulonephritis, Membranoproliferative (1)

Broader conditions

Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Glomerulonephritis (1)  ·  Immune System Diseases (1)  ·  Kidney Diseases (1)  ·  Male Urogenital Diseases (1)  ·  Nephritis (1)  ·  Urogenital Diseases (1)  ·  Urologic Diseases (1)

Interventions

danicopan (1)

Sponsors

Alexion Pharmaceuticals, Inc. (1)

Countries

Australia (1)  ·  Belgium (1)  ·  Italy (1)  ·  Netherlands (1)  ·  United States (1)

Results publications

PMID 36423588

NIH funding

2017 (1)